Tofersen

托夫生

Report date: 2026/02/10 20:00:22
NMEFirst In Class

Base Information

Drug NameTofersen
Drug Alias NameQALSODYQalsody凯盛迪99mTc-MAG3-BIIB067ISIS-333611 +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionSuperoxide dismutase inhibitors
TargetsSuperoxide dismutase
Therapy Area/IndicationsFamilial Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis
Global Approved IndicationsAmyotrophic Lateral Sclerosis
Approved Indications in ChinaAmyotrophic Lateral Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date2023/04/25
Country/TerritoryMainland China(BOAO LECHENG)BelgiumCanada +[18] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIonis Pharmaceuticals IncLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Japan LtdRuijin Hainan HospitalIonis Pharmaceuticals Inc +[7] 
Inactive CompaniesBiogen US CorpWashington University School Of Medicine
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsFamilial Amyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A